{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=42",
    "query": {
      "intervention": "T cells",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 3574,
    "total_pages": 358,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:28:48.462Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04214886",
      "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Acute Lymphoblastic Leukemia, Adult",
        "B-cell Lymphoma Refractory",
        "B-cell Lymphoma Recurrent"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "CD19-CD34 CAR transduced T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Loyola University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-12-31",
      "completion_date": "2034-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-15",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 1,
      "location_summary": "Maywood, Illinois",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214886"
    },
    {
      "nct_id": "NCT06207123",
      "title": "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "LP-118",
          "type": "DRUG"
        },
        {
          "name": "Ponatinib",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-09-13",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Rochester, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06207123"
    },
    {
      "nct_id": "NCT00317759",
      "title": "Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2003-05",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317759"
    },
    {
      "nct_id": "NCT04318327",
      "title": "BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "PHE885",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 96,
      "start_date": "2020-07-23",
      "completion_date": "2025-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04318327"
    },
    {
      "nct_id": "NCT03967223",
      "title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Letetresgene autoleucel (lete-cel, GSK3377794)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "USWM CT, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2019-12-31",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 24,
      "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03967223"
    },
    {
      "nct_id": "NCT02261688",
      "title": "Salt and TH-17 in Healthy Human Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Th17 Helper Immune Cells",
        "Autoimmunity",
        "Salt Intake",
        "Sodium Chloride"
      ],
      "interventions": [
        {
          "name": "Low salt diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low salt diet + IV normal saline",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liberal salt diet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2014-03",
      "completion_date": "2019-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02261688"
    },
    {
      "nct_id": "NCT05257083",
      "title": "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Cilta-cel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stichting European Myeloma Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2023-10-10",
      "completion_date": "2040-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 27,
      "location_summary": "Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05257083"
    },
    {
      "nct_id": "NCT03779854",
      "title": "Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Leukemia",
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Lymphoblastic Leukemia",
        "Acute Undifferentiated Leukemia",
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Blasts Under 25 Percent of Bone Marrow Nucleated Cells",
        "Blasts Under 5 Percent of Bone Marrow Nucleated Cells",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Myelodysplastic Syndrome/Acute Myeloid Leukemia",
        "Burkitt Leukemia",
        "Chronic Monocytic Leukemia",
        "Lymphoblastic Lymphoma",
        "Mast Cell Leukemia",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "6 Months to 26 Years"
      },
      "enrollment_count": 45,
      "start_date": "2019-08-29",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03779854"
    },
    {
      "nct_id": "NCT03728842",
      "title": "Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma; Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Blood collection for laboratory studies",
          "type": "OTHER"
        },
        {
          "name": "Data collection from medical record",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2004-01-04",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03728842"
    },
    {
      "nct_id": "NCT04556266",
      "title": "A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "CAR T-Cell Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-01",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-11-15T14:28:48.462Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04556266"
    }
  ]
}